Kuros Biosurgery develops biomaterials and bioactive biomaterial combination products for indications in trauma, wound and spine.
Kuros Biosciences has raised €18M across 2 funding rounds from 2 investors, most recently a Growth/Late round in Sep 2022. Based in Zurich, Switzerland; founded 2000; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2022-09-16 | Growth/Late | €6.3M | Optiverder B.V,The Netherlands and Pegasus Global Opportunity Fund | View deal → |
| 2019-10-01 | Other | €12M | — | View deal → |
